Antifungal İlaç Zehirlenmeleri
Synopsis
Bu çalışma, 1950'lerden günümüze kadar geliştirilen antifungal ilaçların gelişim sürecini, farmakolojik ile farmakokinetik özelliklerini ve bunlara bağlı gelişen toksisite ile zehirlenme durumlarını ayrıntılı şekilde incelemektedir. Amfoterisin B ile başlayan sistemik antifungal tedavi dönemi; flukonazol, itrakonazol, vorikonazol, posakonazol ve ekinokandinlerin tanımlanmasıyla önemli adımlar kaydetmiş ve invaziv mikoz tedavisinde ilaca bağlı toksisite riskini azaltmıştır. Antifungaller etki mekanizmalarına göre fungal ergosterol sentezini engelleyen azol ve allilaminler, hücre zarını hedef alan polienler (Amfoterisin B) ve hücre duvarındaki β-1,3-d-glukan sentezini inhibe eden ekinokandinler şeklinde sınıflandırılır. İlaçların oral biyoyararlanımı, organ dağılımı, sitokrom P450 (CYP) enzimleri üzerindeki etkileri ve kan-beyin bariyerini geçiş kapasiteleri tedavinin etkinliğini belirleyen temel farmakokinetik unsurlardır. İlaçların klinik kullanımında ketokonazolün karaciğer ve hormonal yan etkileri, Amfoterisin B’nin doz sınırlayıcı nefrotoksisitesi, griseofulvinin teratojenik ile gastrointestinal etkileri ve flusitosinin kemik iliği baskılanması gibi spesifik organ toksisiteleri ortaya çıkabilmektedir. Türkiye’deki klinik veriler acil servise başvuran zehirlenme olguları içinde antimikrobiyal ilaçların %8,98 oranında yer aldığını, vakaların %64,26'sının başvuru anında asemptomatik olduğunu, en sık görülen semptomların ise bulantı-kusma ve taşikardi olduğunu göstermektedir. Sonuç olarak, geliştirilen yeni moleküllere rağmen dar etki spektrumu, karmaşık ilaç etkileşimleri ve uzun süreli kullanım riskleri nedeniyle tüm hastalar için ideal tek bir antifungal ajan mevcut değildir.
This study thoroughly examines the development process of antifungal drugs from the 1950s to the present, their pharmacological and pharmacokinetic properties, and the associated toxicities and poisoning conditions. The systemic antifungal treatment era, which began with Amphotericin B, has made significant progress with the discovery of fluconazole, itraconazole, voriconazole, posaconazole, and echinocandins, reducing the risk of drug-induced toxicity in invasive mycosis therapy. Based on their mechanisms of action, antifungals are classified into azoles and allylamines that inhibit fungal ergosterol synthesis, polyenes (Amphotericin B) that target the cell membrane, and echinocandins that inhibit β-1,3-d-glucan synthesis in the cell wall. Oral bioavailability, organ distribution, effects on cytochrome P450 (CYP) enzymes, and central nervous system penetration are key pharmacokinetic factors determining therapeutic efficacy. In clinical practice, specific organ toxicities may arise, such as ketoconazole's hepatic and hormonal side effects, Amphotericin B's dose-limiting nephrotoxicity, griseofulvin's teratogenic and gastrointestinal effects, and flucytosine's bone marrow suppression. Clinical data from Turkey indicate that antimicrobial drugs account for 8.98% of poisoning cases presenting to the emergency department, with 64.26% of patients being asymptomatic upon admission and nausea-vomiting and tachycardia being the most common symptoms. In conclusion, despite the development of new molecules, an ideal single antifungal agent suitable for all patients does not exist due to narrow activity spectrums, complex drug interactions, and long-term toxicity risks.
References
Rex, J.H., et al., A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med, 1994. 331(20): p. 1325-30.
Kontoyiannis, D.P. and R.E. Lewis, Antifungal drug resistance of pathogenic fungi. Lancet, 2002. 359(9312): p. 1135-44.
Prentice, A.G. and A. Glasmacher, Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother, 2005. 56 Suppl 1: p. i17-i22.
Herbrecht, R., et al., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 2002. 347(6): p. 408-15.
Kauffman, C.A., et al., Posaconazole. Nat Rev Drug Discov, 2007. 6(3): p. 183-4.
Rachwalski, E.J., J.T. Wieczorkiewicz, and M.H. Scheetz, Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother, 2008. 42(10): p. 1429-38.
Wingard, J.R., et al., Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010. 116(24): p. 5111-8.
Ullmann, A.J., et al., Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med, 2007. 356(4): p. 335-47.
Girmenia, C., New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs, 2009. 18(9): p. 1279-95.
Pappas, P.G., et al., Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis, 2007. 45(7): p. 883-93.
Sheehan, D.J., C.A. Hitchcock, and C.M. Sibley, Current and emerging azole antifungal agents. Clin Microbiol Rev, 1999. 12(1): p. 40-79.
Odds, F.C., A.J. Brown, and N.A. Gow, Antifungal agents: mechanisms of action. Trends Microbiol, 2003. 11(6): p. 272-9.
Mann, P.A., et al., Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother, 2003. 47(2): p. 577-81.
Ryder, N.S., Activity of terbinafine against serious fungal pathogens. Mycoses, 1999. 42 Suppl 2: p. 115-119.
Brajtburg, J., et al., Amphotericin B: delivery systems. Antimicrob Agents Chemother, 1990. 34(3): p. 381-4.
Groll, A.H., S.C. Piscitelli, and T.J. Walsh, Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol, 1998. 44: p. 343-500.
Cleary, J.D., P.D. Rogers, and S.W. Chapman, Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy, 2003. 23(5): p. 572-8.
Saliba, F. and B. Dupont, Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol, 2008. 46(2): p. 97-112.
Chamilos, G. and D.P. Kontoyiannis, Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat, 2005. 8(6): p. 344-58.
Douglas, C.M., et al., Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother, 1997. 41(11): p. 2471-9.
Diasio, R.B., J.E. Bennett, and C.E. Myers, Mode of action of 5-fluorocytosine. Biochem Pharmacol, 1978. 27(5): p. 703-7.
Johnston, A., The pharmacokinetics of voriconazole. Br J Clin Pharmacol, 2003. 56 Suppl 1(Suppl 1): p. 1.
Krishna, G., et al., Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother, 2009. 53(3): p. 958-66.
Walsh, T.J., et al., Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother, 2010. 54(10): p. 4116-23.
Brüggemann, R.J., et al., Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis, 2009. 48(10): p. 1441-58.
Lewis, R.E., Managing drug interactions in the patient with aspergillosis. Med Mycol, 2006. 44(Supplement_1): p. S349-s356.
Saad, A.H., D.D. DePestel, and P.L. Carver, Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy, 2006. 26(12): p. 1730-44.
Imai, J.K., et al., Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother, 2004. 48(10): p. 4063-6.
Tucker, R.M., et al., Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis, 1992. 14(1): p. 165-74.
Araz, C., et al., Evaluating the poisoning cases in Ümraniye Training and Research Hospital Pediatric Emergency Department. Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2017. 13: p. 57-67.